Vor Bio, a clinical-stage biotechnology company based in Cambridge, Mass., and listed on Nasdaq under the ticker symbol VOR, has disclosed the issuance of inducement grants to new employees as per Nasdaq Listing Rule 5635(c)(4. The grants, approved by the Compensation Committee of the Board of Directors between August 4, 2025, and August 18, 2025, include stock options to acquire 6,959,013 shares of Vor Bio’s common stock and restricted stock units (RSUs) representing the right to receive 1,491,217 shares of the company’s common stock. These grants were offered to seven recently onboarded employees to incentivize their employment with Vor Bio. The issuance was executed under the Vor Biopharma Inc. 2023 Inducement Plan.
The stock options granted to the new employees have a duration of ten years and feature exercise prices ranging from $2.11 to $2.04 per share, mirroring the closing price of Vor Bio’s common stock on the respective grant dates. Vesting of these options will occur over a four-year period, with 25% of the shares becoming available after 12 months and the remaining shares vesting on a monthly basis over the subsequent 36 months. The vesting of RSUs follows a similar timeline, with 25% of the shares vesting after 12 months and the rest on a quarterly schedule over the ensuing 36 months. The continued employment of the recipients with Vor Bio is a prerequisite for the vesting of these options and RSUs, in accordance with the terms and conditions outlined in the Inducement Plan and the associated award agreement.
Vor Bio’s primary focus lies in revolutionizing the treatment landscape for autoimmune diseases. The company is dedicated to the swift progression of telitacicept, a groundbreaking dual-target fusion protein, through Phase 3 clinical trials and subsequent commercialization efforts aimed at addressing severe autoantibody-mediated conditions on a global scale. To learn more about Vor Bio and its innovative initiatives in autoimmune disease therapy, interested parties can visit the company’s official website at www.vorbio.com.
For further information or inquiries from the media or potential investors, individuals can reach out to Carl Mauch at cmauch@vorbio.com. Vor Bio remains committed to advancing the frontiers of biotechnology and enhancing the standard of care for individuals grappling with autoimmune disorders.
Key Takeaways:
– Vor Bio has granted stock options and RSUs to new employees as inducements for joining the company, aligning with Nasdaq regulations.
– The stock options and RSUs issued have specific exercise prices and vesting schedules tied to the duration of the employees’ continued tenure with Vor Bio.
– Telitacicept, a dual-target fusion protein, represents Vor Bio’s flagship product in the realm of autoimmune disease treatment, currently progressing through Phase 3 trials.
– For media and investor inquiries regarding Vor Bio and its activities, Carl Mauch can be contacted at cmauch@vorbio.com.
Tags: biopharma
Read more on finance.yahoo.com